Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2020

Other current assets consisted of the following as of March 31, 2020 and December 31, 2019:

	March 31, 2020		December 31, 2019
	(unaudited)
Lab supply inventory		1,885		1,825
Prepaid expenses		826		971
Funds in escrow		888		888
Due from CGI		1,297		92
Other		80		75
Total other current assets	$	4,976	$	3,851

Schedule of Basic and Diluted Net Loss Per Share

A reconciliation of the number of shares of common stock, par value $0.01 per share (the “Common Stock”), used in the calculation of basic and diluted loss per share for the three-month periods ended March 31, 2020 and 2019 is as follows:

	Three Months Ended
	March 31,
	2020		2019
		(unaudited)
Basic weighted average number of common shares		4,004		3,515
Potential dilutive effect of stock-based awards		-		-
Diluted weighted average number of common shares		4,004		3,515

Schedule of Computation of Dilutive Securities

The following outstanding stock-based awards and warrants were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

	Three Months Ended
	March 31,
	2020		2019
	(unaudited)
Options		578		394
Stock-settled stock appreciation rights (SARs)		-		3
Restricted stock		6		-
Restricted stock units (RSUs)		36		61
Warrants		1,420		1,420
		2,040		1,878